まとめ
ニトログリセリンとイソソorbide dinitrateは,尿中の2,3-dinor-6-keto-PGF1α分泌によって測定されたプロスタサイクリン合成に影響を与えませんでした. この研究では,以前の侵襲的な技術からの混乱要因を回避するために,非侵襲的な方法を使用しました.
科学分野:
- 心血管薬理学について
- 生化学分析 バイオケミカル分析
背景:
- 以前の研究では,ニトログリセリンがプロスタサイクリン放出を刺激すると示唆されていました.
- 侵襲的な心臓キャセテリゼーション方法は,プロスタサイクリンの放出を刺激することによって,これらの発見を混乱させることがあります.
- プロスタサイクリン合成に対する窒素酸塩の影響を正確に評価するには,非侵襲的な方法が必要です.
研究 の 目的:
- 短効性 (ニトログリセリン) と長効性 (イソソルビド二酸化物) の窒素がプロスタサイクリン合成に及ぼす影響を調査する.
- プロスタサイクリン合成を測定するために,非侵襲的な指数である尿中の2,3-ディノール-6-ケト-PGF1アルファ分泌を使用します.
- プロスタサイクリン放出を人工的に刺激する侵襲的な方法の限界を克服するために.
主な方法:
- 6人の被験者は,ニトログリセリン注入を受けた.
- 尿中の2,3-ディノール-6-ケト-PGF1アルファは,ニトログリセリン注入前,中,および後のガス染色体質スペクトロメトリーを使用して測定されました.
- 血小板の集積と血清トロンボキサンB2レベルもex vivoで評価した.
主要な成果:
- ニトログリセリン注入は,尿中の2,3-ディノール-6-ケト-PGF1アルファ分泌を有意に変化させなかった.
- 血小板の集積は1人の被験者にのみ抑制され,プロスタサイクリンの代謝産物分泌は変化しませんでした.
- 血清トロンボキサンB2濃度は,ニトログリセリン注入中に変化しませんでした.
結論:
- 短期間および長期にわたって作用する窒素は,生体内ではプロスタサイクリン合成を刺激しないようです.
- 尿中の2,3-ディノール-6-ケト-PGF1αの非侵襲的測定は,プロスタサイクリン合成の信頼できる指標を提供します.
- 発見は,潜在的に混乱を招く侵襲的な技術に基づく以前の結論に異議を唱える.
関連する概念動画
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...